Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery

Journal of Peptide Science

Volumn 19, Issue 4, 2013, Pages 190-197

  Accardo, Antonella ^a   Mangiapia, Gaetano ^a   Paduano, Luigi ^a   Morelli, Giancarlo ^a   Tesauro, Diego ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Doxorubicin; Drug delivery; Octreotide; Platinum complexes; SANS; Supramolecular aggregates

Indexed keywords

AMPHOPHILE; DOXORUBICIN; LIPOSOME; MACROGOL; NANOCARRIER; OCTREOTIDE; PLATINUM COMPLEX;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; LIGHT SCATTERING; NANOENCAPSULATION; NEUTRON SCATTERING; PH; PRIORITY JOURNAL; THICKNESS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; CISPLATIN; DOXORUBICIN; DRUG DELIVERY SYSTEMS; LIPOSOMES; OCTREOTIDE; PLATINUM; RECEPTORS, SOMATOSTATIN;

EID: 84875626479     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2481     Document Type: Article

References (48)

1. Lippert B. Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug. Wiley-VCH: Weinheim, 1999.
2. Burger KNJ, Staffhorst RWHM, de Kruijff B. Interaction of the anti-cancer drug cisplatin with phosphatidylserine in intact and semi-intact cells. Biochim. Biophys. Acta 1999; 1419: 43-54.
3. Reedijk J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell. Chem. Rev. 1999; 99: 2499-2510.
4. Howe-Grant ME, Lippard SJ. Aqueous platinum(II) chemistry; binding to biological molecules. In Metal Ions in Biological Systems, Vol. XI, Sigel H (ed.). M. Dekker: New York, 1980; 63-125.
5. Long DF, Repta AJ. Cisplatin: chemistry, distribution and biotransformation. Biopharm. Drug Dispos. 1981; 2: 1-16.
6. Herman EH, Rahman A, Ferrans VJ, Vick JA, Schein PS. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 1983; 43: 5427-5432.
7. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 1999; 43: 1-7.
8. Sur B, Ray RR, Sur P, Roy DK. Effect of liposomal encapsulation of cis-platinum diamminodichloride in the treatment of Ehrlich ascites carcinoma. Oncology 1983; 40: 372-376.
9. Steerenberg PA, Storm G, de Groot G, Claessen A, Bergers JJ, Franken MAM, van Hoesel QGCM, Wubs KL, de Jong WH. Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). Cancer Chemother. Pharmacol. 1988; 21: 299-307.
10. Perez-Soler R, Shin DM, Siddik ZH, Murphy WK, Huber M, Lee SJ, Khokhar AR, Hong WK. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin. Cancer Res. 1997; 3: 373-379.
11. Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DM. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2005; 23: 3495-3501.
12. Insook H, Khokhar AR, Perez-Soler R. Intraliposomal conversion of lipophilic cis-bis-carboxylato-trans-R, R-1, 2-diaminocyclohexane-platinum (II) complexes into cis-bis-dichloro-trans-R, R -1, 2-diaminocyclohexane-platinum (II). Cancer Chemother. Pharmacol. 1996; 39: 17-24.
13. Kim DK, Gam J, Kim HT, Kim KH. Synthesis and in vitro cytotoxicity of cis-(glycolato-O, O′)-[2-substituted-(4R, 5R)-4, 5-bis(aminomethyl)-1, 3-dioxolane]platinum(II). Bioorg. Med. Chem. Lett. 1996; 6: 771-774.
14. Liu WP, Ye QS, Yu Y, Chen XZ, Hou SQ, Lou LG, Yang YP, Wang YM, Su Q. Novel lipophilic Platinum(II) compounds of salicylate derivatives. Platinum Metals Rev. 2008; 52: 163-170.
15. Stathopoulos GP, Boulikas T. Lipoplatinum formulation review articles. J. Drug Deliv. 2012; 1-10.
16. Burger KNJ, Staffhorst RWHM, de Vijlder HC, Velinova MJ, Bomans PH, Frederik PM, de Kruijff B. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat. Med. 2002; 8: 81-84.
17. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 1997; 154: 123-140.
18. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, Peters AM, Stewart JS. Phase I-II study of pegylated liposomal ciplastin (SPI-077) in patients with inoperable head and neck cancer. Ann. Oncol. 2001; 12: 493-496.
19. Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anti Canc. Drugs 1999; 10: 911-920.
20. Velinova MJ, Staffhorst RWHM, Mulder WJM, Dries AS, Jansen BAJ, de Kruijff B, de Kroon AIPM. Preparation and stability of lipid-coated nanocapsules of cisplatin: anionic phospholipid specificity. Biochim. Biophys. Acta 2004; 1663: 135-142.
21. Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother. Pharmacol. 2004; 53: 329-336.
22. White SC, Lorigan P, Margison GP, Margison JM, Martin F, Thatcher N, Anderson H, Ranson M. Phase II study of SPI-77 (sterically stabilized liposomal cisplatin) in advanced NSCLC. Br. J. Cancer 2006; 95: 822-828.
23. Rosenthal DI, Yom SS, Liu L, Machtay M, Algazy K, Weber RS, Weinstein GS, Chalian AA, Miller LK, Rockwell K, Tonda M, Schnipper E, Hershock D. A Phase I study of SPI-77 (stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest. New Drugs 2002; 20: 343-349.
24. Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben Matthijs M, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest E, Beijnen JH, Schellens JH. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother. Pharmacol. 2002; 49: 201-210.
25. Lazarioti F, Boulikas T. Diagnostic and therapeutic efficacy of imaging modalities in non-small cell lung cancer (NSCLC): experience from a Phase III clinical study using tumor targeted lipoplatin nanoparticles. Canc. Ther. 2008; 6: 629-646.
26. Boulikas T, Pantos A, Bellis E, Christofis P. Designing platinum compounds in cancer: structures and mechanisms. Canc. Ther. 2007; 5: 537-583.
27. Chen H, Pazicni S, Krett NL, Ahn RW, Penner-Hahn JE, Rosen ST, Halloran TVO. Coencapsulation of arsenic- and platinum based drugs for targeted cancer treatment. Angew. Chem. Int. Ed. 2009; 48: 9295-9299.
28. Accardo A, Morisco A, Tesauro D, Pedone C, Morelli G. Naposomes: a new class of peptide derivatized target selective multimodal nanoparticles for imaging and therapeutic applications. Ther. Deliv. 2011; 2: 235-257.
29. Accardo A, Tesauro D, Morelli G, Gianolio E, Aime S, Vaccaro M, Mangiapia G, Paduano L, Schillen K. High-relaxivity supramolecular aggregates containing peptide and Gd complexes agents in MRI. J. Biol. Inorg. Chem. 2007; 12: 267-276.
30. Tesauro D, Accardo A, Gianolio E, Paduano L, Teixeira J, Schillén K, Aime S, Morelli G. Peptide derivatized lamellar aggregates as target-specific MRI contrast agents. Chembiochem 2007; 8: 950-955.
31. Vaccaro M, Mangiapia G, Paduano L, Gianolio E, Accardo A, Tesauro D, Morelli G. Structural and relaxometric characterization of peptide aggregates containing gadolinium complexes as potential selective contrast agents in MRI. Chemphyschem 2007; 8: 2526-2538.
32. Accardo A, Mansi R, Morisco A, Mangiapia G, Paduano L, Tesauro D, Radulescu A, Aurilio M, Aloj L, Arra C, Morelli G. Peptide modified nanocarriers for selective targeting of bombesin receptors. Mol. Biosyst. 2010; 6: 878-887.
33. Anelli PL, Lattuada L, Lorusso V, Schneider M, Tournier H, Uggeri F. Mixed micelles containing lipophilic gadolinium complexes as MRA contrast agents. Magn. Res. Mater Phys. Biol. Med. 2001; 12: 114-120.
34. Accardo A, Morisco A, Gianolio E, Tesauro D, Mangiapia G, Radulescu A, Brandte A, Morelli G. Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications. J. Pept. Sci. 2011; 16: 154-162.
35. Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov AJ, Trubetskoy VS, Herron JN, Gentry CA. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta 1994; 119: 11-20.
36. Robillard MS, van Alphen S, Meeuwenoord NJ, Jansen BAJ, van der Marel GA, van Boomw JH, Reedjiak J. Solid-phase synthesis of peptide-platinum complexes using platinum-chelating building blocks derived from amino acids. New J. Chem. 2004; 29: 220-225.
37. Edelhoch H. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 1967; 6: 1948-1954.
38. Vergara A, Paduano L, Sartorio R. Multicomponent diffusion in solutions containing solutes of different molecular size. 4. Ternary system Tetra(ethyleneglycol)-Di(etyleneglycol)-water. J. Phys. Chem. B 2001; 105: 328-334.
39. Ma G, Barlow DJ, Lawrence MJ, Heenan RK, Timmins P. Small-angle neutron-scattering studies of nonionic surfactant vesicles. J. Phys. Chem. B 2000; 104: 9081-9085.
40. Tardi PG, Boman NL, Cullis PR. Liposomal doxorubicin. J. Drug Target. 1996; 4: 129-140.
41. Gabizon AA. The quest for the magic bullet stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin. Cancer Res. 2001; 7: 223-225.
42. Borrelli A, Schiattarella A, Musella A, Mancini R, Capasso C, De Luca V, Carginale V, Sanseverino M, Tornesello AL, Gori E, Pica A, Di Santi A, Basile F, Iacobellis F, Colacurci N, Cobellis L, Mancini A. A molecular carrier to transport and deliver cisplatin into endometrial cancer cells. Chem. Biol. Drug Des. 2012; 1-8.
43. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 2010; 28: 3323-3329.
44. Schmitt L, Dietrich C, Tampe R. Synthesis and characterization of chelator-lipids for reversible immobilization of engineered proteins at self-assembled lipid interfaces. J. Am. Chem. Soc. 1994; 116: 8485-8491.
45. Chang WC, White PD. Fmoc Solid Phase Peptide Synthesis. Oxford University Press: New York, USA, 2000.
46. Brehm GA, Bloomfield VA. Analysis of polydispersity in polymer solutions by inelastic laser light scattering. Macromolecules 1975; 8: 663-665.
47. Russell TP, Lin JS, Spooner S, Wignall GD. Intercalibration of small-angle X-ray and neutron scattering data. J. Appl. Crystallogr. 1988; 21: 629-638.
48. Wignall GD, Bates FS. Absolute calibration of small-angle neutron scattering data. J. Appl. Crystallogr. 1987; 20: 28-40.